Noriyuki Namba
0000-0002-3803-4500
8 papers found
Refreshing results…
Burosumab treatment of X-linked hypophosphatemia patients: interim analysis of the SUNFLOWER longitudinal, observational cohort study
Difference in TMPRSS2 usage by Delta and Omicron variants of SARS-CoV-2: Implication for a sudden increase among children
Febrile seizure in children with COVID-19 during the Omicron variant-predominant era: A single-center study
Clinical characteristics of and growth hormone treatment effects on short stature with type 1 insulin-like growth factor receptor (<i>IGF1R</i>) gene alteration
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia
IGF2 Mutations
Missing publications? Search for publications with a matching author name.